Screening and value of novel myositis specific antibodies in predicting dermatomyositis associated with interstitial lung disease and malignant tumors

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300071887

Enrollment

Unknown

Registered

2023-05-29

Start date

2023-06-01

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatomyositis

Interventions

Part I: Bidirectional cohort study to study the correlation between cancer incidence and MSAs antibody in dermatomyositis patients:N/A

Part II:Case control study on the correlation between interstitial lung disease and MSAs antibodies in patients with dermatomyositis:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Part I: Bidirectional cohort study to study the correlation between cancer incidence and MSAs antibody in dermatomyositis patients Inclusion criteria: All included patients met the classification criteria for idiopathic inflammatory myopathy in 2017- EULAR/ACR. The onset age of the disease is greater than 18 years old. Case control study on the correlation between interstitial lung disease and MSAs antibodies in patients with dermatomyositis Inclusion criteria: All included patients met the classification criteria for idiopathic inflammatory myopathy in 2017- EULAR/ACR. The onset age of the disease is approximately 18 years old. Interstitial lung disease occurred at the time of inclusion: The HRCT manifestations of the patient's chest include ground glass shadow, consolidation shadow, reticular shadow, honeycomb shadow, irregular linear shadow, strip shadow, and traction bronchiectasis.

Exclusion criteria

Exclusion criteria: Part I: Bidirectional cohort study to study the correlation between cancer incidence and MSAs antibody in dermatomyositis patients Part II:Case control study on the correlation between interstitial lung disease and MSAs antibodies in patients with dermatomyositis The exclusion criteria are all patients with overlapping syndrome, inclusion body myositis, immune mediated necrotizing myositis and muscular dystrophy, metabolic and drug related myopathy. Or patients who cannot cooperate with follow-up, do not agree to be included in the group, or have mental illness.

Design outcomes

Primary

Measure	Time frame
cancer;Interstitial lung disease;	—

Secondary

Measure	Time frame
death rate;	—

Countries

China

Contacts

Public ContactXiaojing Xing

Capital Medical University Affiliated Beijing Shijitan Hospital

xingxiaojing1985@163.com+86 135 0132 0496

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026